1-(diphenylmethyl)-4-propylpiperazine | 48192-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(diphenylmethyl)-4-propylpiperazine
• 英文别名: N¹-n-Propyl-(1)-N⁴-benzhydryl-piperazin；1-benzhydryl-4-propyl-piperazine；1-Benzhydryl-4-propylpiperazine
• CAS: 48192-24-1
• 化学式: C₂₀H₂₆N₂
• 分子量: 294.44
• InChiKey: XSKWLXBVZNJSSP-UHFFFAOYSA-N

物化性质

• 熔点：
  70 °C
• 沸点：
  393.2±32.0 °C(Predicted)
• 密度：
  1.033±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  二苯甲基哌嗪 、 1-碘代丙烷 在 碳酸氢钠 作用下， 以 苯 为溶剂， 以53.3%的产率得到1-(diphenylmethyl)-4-propylpiperazine
  参考文献：
  名称：

  Percutaneous absorption of cyclizine and its alkyl analogues

  摘要：

  Cyclizine (I) alkyl analogues (II-IV) were synthesized and their skin permeation parameters evaluated in vitro. It was hoped that these compounds would possess physicochemical properties more favourable for percutaneous delivery than (I). The identification and levels of purity for the compounds were confirmed by mass spectrometry (MS), nuclear magnetic resonance (NMR) spectrometry, and infrared spectrometry (IR) while melting points were determined by an electrothermal digital Bupsilonchi melting point apparatus. Aqueous solubilities (25 degrees C) and partition coefficients were determined and in vitro permeation studies were performed in buffer (37 degrees C) at pH 7.4 over a period of 24 h, using Franz diffusion cells fitted with human epidermal membranes. Generally, the analogues were more lipophilic, but nevertheless possessed higher aqueous solubilities as compared to (I). (II) and (IV) exhibited two- to three-fold increase in aqueous solubility and their melting temperatures dropped by more than 55 degrees C. Compound (III) had similar aqueous solubility to (I), but its melting point dropped by about 35 degrees C. Measured steady-state fluxes indicated that (II) is a far better penetrant (J=6.95 microg/cm(2)/h) of human epidermis than (I). Although fluxes of (III) and (IV) drop off markedly from that of (II), they remained above the flux of (I), which is (0.132 microg/cm(2)/h). In conclusion, (II) was the best skin permeant and also exhibited the highest aqueous solubility and lowest level of crystallinity as compared to (I) and other analogues. (III) and (IV) were more lipophilic. The overall permeation data of this series indicated that the more water-soluble and the lowest melting point compound was the best skin permeant.

  DOI：

  10.1016/j.ejps.2004.11.001

文献信息

• Pharmaceutical agents for the treatment of cerebral amyloidosis
  申请人：NYMOX CORPORATION

  公开号：EP1930308A1

  公开（公告）日：2008-06-11

  The invention relates to a compound of the following general formula (III): wherein: R1 and R2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and carboxyl; R3 is selected from the group consisting of amino, C1-C5 substituted amino and CH2; n and m are independently an integer of from 0-5; or a pharmaceutically acceptable salt of such compound; a compound of the following general formula (IV): wherein: R1 and R2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and ca rboxyl; R3 and R4 each are independent and selected from the group consisting of hydrogen and C1-C5 alkyl; n is an integer of from 1 to 5; or a pharmaceutically acceptable salt of such compound; a compound of the following general formula (V): wherein: R1 and R2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and carboxyl; R3 is selected from hydrogen and C1-C5 alkyl; R4 is selected from hydrogen and C1-C5 alkyl; n is an integer of from 1 to 5 inclusive; or a pharmaceutically acceptable salt of such compound; and a compound of the following general formula (VI): wherein: R1 and R2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and carboxyl; R3 and R4 each are independent and selected from hydrogen and C1-C5 alkyl; n is an integer of from 1 to 5 inclusive; or a pharmaceutically acceptable salt of such compound. Also compositions comprising the compounds III-VI as well as uses of said compounds.

  本发明涉及以下通式 (III) 的化合物： 其中 R1和R2各自为一个或多个独立取代基，选自由氢、C1-C5烷基、C2-C5烯基、C3-C5环烷基、C1-C5烷氧基、C2-C5炔基、卤素、C1-C5卤代烷基、烷基氨基、苯基、硝基和羧基组成的组； R3 选自氨基、C1-C5 取代的氨基和 CH2 组成的组； n 和 m 独立地为 0-5 之间的整数； 或此类化合物的药学上可接受的盐； 以下通式（IV）的化合物： 其中 R1和R2各自是一个或多个独立的取代基，选自由氢、C1-C5烷基、C2-C5烯基、C3-C5环烷基、C1-C5烷氧基、C2-C5炔基、卤素、C1-C5卤代烷基、烷基氨基、苯基、硝基和羧基组成的组； R3 和 R4 各自独立，选自由氢和 C1-C5 烷基组成的组； n 是 1 至 5 的整数； 或此类化合物的药学上可接受的盐； 以下通式(V)的化合物： 其中 R1和R2各自为一个或多个独立取代基，选自由氢、C1-C5烷基、C2-C5烯基、C3-C5环烷基、C1-C5烷氧基、C2-C5炔基、卤素、C1-C5卤代烷基、烷基氨基、苯基、硝基和羧基组成的组； R3 选自氢和 C1-C5 烷基； R4 选自氢和 C1-C5 烷基； n 是 1 至 5（包括 5）的整数； 或此类化合物的药学上可接受的盐；以及 以下通式(VI)的化合物： 其中 R1和R2各自是一个或多个独立的取代基，选自由氢、C1-C5烷基、C2-C5烯基、C3-C5环烷基、C1-C5烷氧基、C2-C5炔基、卤素、C1-C5卤代烷基、烷基氨基、苯基、硝基和羧基组成的组； R3 和 R4 各自独立，选自氢和 C1-C5 烷基； n 是 1 至 5（包括 5）的整数； 或此类化合物的药学上可接受的盐。 还包括由化合物 III-VI 组成的组合物以及所述化合物的用途。
• Solid dispersion tablets containing 1,4-dihydropyridine derivatives and process for the preparation thereof
  申请人：Fujirebio Inc.

  公开号：EP0521310B1

  公开（公告）日：1999-01-20
• NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE
  申请人：Université Amiens Picardie Jules Verne

  公开号：EP3704093A1

  公开（公告）日：2020-09-09
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
• US7414048B2
  申请人：——

  公开号：US7414048B2

  公开（公告）日：2008-08-19